Citius Pharmaceuticals Inc Stock

$1.01

14.83% today

Nasdaq, Apr 03, 06:42 pm CET

ISIN

US17322U2078

Symbol

CTXR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Citius Pharmaceuticals Inc Stock price

$1.18

-17.32 93.62% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

-0.02 1.67%

ISIN

US17322U2078

Symbol

CTXR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$10.14m
Enterprise Value	$12.75m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.14
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-42.69m
Free Cash Flow (TTM) Free Cash Flow	$-26.79m
Cash position	$1.10m
EPS (TTM) EPS	$-5.80
P/E forward	0.87
P/S forward	0.66
EV/Sales forward	0.83
Short interest	6.39%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Citius Pharmaceuticals Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Citius Pharmaceuticals Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.21 0.21	5% 5% -
Gross Profit	-0.21 -0.21	5% 5% -
- Selling and Administrative Expenses	31 31	26% 26% -
- Research and Development Expense	11 11	19% 19% -
EBITDA	-42 -42	10% 10% -
- Depreciation and Amortization	0.21 0.21	5% 5% -
EBIT (Operating Income) EBIT	-43 -43	10% 10% -
Net Profit	-40 -40	4% 4% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Citius Pharmaceuticals Inc Stock News

Neutral

PRNewsWire

●

2 days ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

CRANFORD, N.J. , April 1, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of 1,739,131 shares of its common stock (or pre-funded warrants in li...

Neutral

PRNewsWire

●

about 2 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.

Neutral

PRNewsWire

●

about 2 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J.

More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office	United States
CEO	Leonard Mazur
Employees	23
Founded	2007
Website	www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now